Next-Generation Therapeutics: Anti-Amyloid & Anti-Tau Innovations

Next-generation therapeutics targeting amyloid and tau are reshaping the landscape of Alzheimer’s treatment. New anti-amyloid antibodies, tau aggregation inhibitors, small-molecule stabilizers, and dual-pathway modulators aim to reduce neurotoxic buildup and preserve neural networks. These therapies combine improved safety profiles with precision dosing and biomarker-guided monitoring. Advances in drug delivery systems increase blood–brain barrier penetration, maximizing therapeutic impact. Combination therapies that simultaneously target amyloid, tau, and inflammatory pathways show promise in modifying disease trajectories. Continuous clinical research is refining efficacy, identifying ideal treatment windows, and enabling earlier intervention. These innovations signal a major shift toward disease-modifying approaches capable of addressing core pathology.

    Related Conference of Next-Generation Therapeutics: Anti-Amyloid & Anti-Tau Innovations

    February 05-06, 2026

    9th Annual Conference on Skin Cancer and Dermatology

    Paris, France
    April 16-17, 2026

    9th World Cosmetic and Dermatology Congress

    Paris, France
    June 15-16, 2026

    COSMETIC DERMATOLOGY 2026

    Paris, France
    June 22-23, 2026

    28th World Dermatology and Aesthetic Congress

    London, UK
    June 25-26, 2026

    27th World Dermatology Congress

    Paris, France
    July 20-21, 2026

    20th International Conference on Alzheimers Disease & Dementia

    Amsterdam, Netherlands
    August 25-26, 2026

    26th European Dermatology Congress

    Paris, France

    Next-Generation Therapeutics: Anti-Amyloid & Anti-Tau Innovations Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in